{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ribavirin+%28R%29", "query": { "intervention": "Ribavirin (R)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ribavirin+%28R%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T19:46:56.419Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02167945", "title": "A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus (HCV) Infection Genotype 1" ], "interventions": [ { "name": "ABT-450/r/ABT-267", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 615, "start_date": "2014-06-12", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-09-24T19:46:56.419Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02167945" }, { "nct_id": "NCT01467479", "title": "A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a", "type": "BIOLOGICAL" }, { "name": "Highly Active Antiretroviral Therapy (HAART)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 185, "start_date": "2011-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-03-17", "last_synced_at": "2026-09-24T19:46:56.419Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467479" }, { "nct_id": "NCT01221298", "title": "A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HCV", "Chronic Hepatitis C Infection", "Hepatitis C Genotype 1" ], "interventions": [ { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-072", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2010-10", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-09-24T19:46:56.419Z", "location_count": 4, "location_summary": "Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01221298" }, { "nct_id": "NCT01581203", "title": "Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Asunaprevir (ASV)", "type": "DRUG" }, { "name": "Daclatasvir (DCV)", "type": "DRUG" }, { "name": "Pegylated-interferon alfa 2a (PegIFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 748, "start_date": "2012-05", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-24T19:46:56.419Z", "location_count": 18, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01581203" }, { "nct_id": "NCT01306617", "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection", "Hepatitis C", "Hepatitis C Virus" ], "interventions": [ { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2011-02", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-09-24T19:46:56.419Z", "location_count": 11, "location_summary": "Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01306617" }, { "nct_id": "NCT01563536", "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection" ], "interventions": [ { "name": "ABT-267", "type": "DRUG" }, { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 12, "start_date": "2012-02", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-09-24T19:46:56.419Z", "location_count": 4, "location_summary": "Bakersfield, California • Orlando, Florida • Annapolis, Maryland + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Annapolis", "state": "Maryland" }, { "city": "Poughkeepsie", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01563536" }, { "nct_id": "NCT01467505", "title": "An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a", "type": "DRUG" }, { "name": "Immunosuppressant Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 61, "start_date": "2012-02", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-06-18", "last_synced_at": "2026-09-24T19:46:56.419Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467505" }, { "nct_id": "NCT00980330", "title": "A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peg-IFN-alfa-2a (P)", "type": "DRUG" }, { "name": "Ribavirin (R)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 463, "start_date": "2009-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-09-24T19:46:56.419Z", "location_count": 17, "location_summary": "La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00980330" }, { "nct_id": "NCT01241760", "title": "VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Genotype 1 Chronic Hepatitis C", "Treatment Naive" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Infectious Diseases BVBA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 744, "start_date": "2010-12", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-09-24T19:46:56.419Z", "location_count": 37, "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 34 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01241760" }, { "nct_id": "NCT02194998", "title": "Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)", "type": "DRUG" }, { "name": "Dasabuvir (DSV)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 46, "start_date": "2015-09-16", "completion_date": "2018-11-13", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-24T19:46:56.419Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02194998" } ] }